Iterum Therapeutics Files 8-K on Shareholder Vote Matters

TL;DR

Iterum Therapeutics (ITRM) shareholders voting on key company matters.

AI Summary

On June 19, 2024, Iterum Therapeutics plc filed an 8-K report detailing the submission of matters to a vote of security holders. The filing also includes other events and financial statements and exhibits. The company is incorporated in Ireland and its principal executive offices are located in Dublin.

Why It Matters

This filing indicates important corporate actions are being put to a vote by Iterum Therapeutics' shareholders, which could impact the company's future direction and governance.

Risk Assessment

Risk Level: medium — Filings related to shareholder votes can signal significant corporate changes or potential disagreements, which carry inherent risks.

Key Players & Entities

• Iterum Therapeutics plc (company) — Registrant
• Ireland (location) — Jurisdiction of Incorporation
• Dublin 2 (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.01 — registered Ordinary Shares, par value $0.01 per share ITRM The Nasdaq Stock Mar

Filing Documents

• itrm-20240619.htm (8-K) — 66KB
• itrm-ex99_1.htm (EX-99.1) — 13KB
• 0000950170-24-075885.txt ( ) — 201KB
• itrm-20240619.xsd (EX-101.SCH) — 26KB
• itrm-20240619_htm.xml (XML) — 5KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 19, 2024, Iterum Therapeutics plc ( the " Company ") held its 2024 annual general meeting (the " AGM "), at which the Company's shareholders voted on the following proposals, each of which is described in the Company's definitive proxy statement (the " Proxy Statement "), filed with the Securities and Exchange Commission on April 26, 2024. Proposal No. 1: Election of Directors. The shareholders elected, by separate resolutions, Corey Fishman and Ronald Hunt to the Company's board of directors as Class III directors, each to serve for a three-year term expiring at the Company's 2027 annual general meeting of shareholders. The results of the shareholders' vote for the election of such Class III directors were as follows: Nominee For Against Abstain Broker Non-Votes Corey Fishman 1,807,302 751,976 44,598 4,069,360 Ronald Hunt 1,450,446 1,108,449 44,981 4,069,360 Proposal No. 2: Ratification of Appointment of the Company's Independent Registered Public Accounting Firm for 2024 and Authorization of the Board of Directors to Approve the Remuneration of the Independent Registered Public Accounting Firm. The shareholders ratified, in a non-binding vote, the appointment of KPMG as the Company's independent registered public accounting firm for its fiscal year ended December 31, 2024 and authorized the Company's board of directors, acting through its audit committee, to set the independent registered public accounting firm's remuneration. The results of the shareholders' vote were as follows: For Against Abstain 5,481,253 1,126,772 65,211 Proposal No. 3: Advisory vote on the compensation of the Company's Named Executive Officers. The shareholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement. The results of the shareholders' vote were as follows: For Against A

01 Other Events

Item 8.01 Other Events. On June 20, 2024, Iterum Therapeutics plc issued a press release announcing that the U.S. Food and Drug Administration (FDA) has determined that the New Drug Application (NDA) for sulopenem etzadroxil/probenecid (oral sulopenem) for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women will be taken to Advisory Committee, with September 9, 2024 being the proposed date for the Advisory Committee meeting. In its communication, the FDA highlighted that the purpose of the Advisory Committee was to discuss a) antimicrobial stewardship issues raised by potential approval and subsequent use of what would be the first oral penem in the U.S.; and b) the most appropriate target patient population(s) for treatment of uUTI with oral sulopenem. The full text of the press release issued in connection with this announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of Iterum Therapeutics plc dated June 21, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Iterum Therapeutics plc Date: June 21, 2024 By: /s/ Corey N. Fishman Corey N. Fishman Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR